The clinical-stage firm bolstered its balance sheet during the second quarter, securing $4.5 million through a registered direct offering that could yield an additional $12 million. These funds are earmarked to accelerate the development of (Z)-endoxifen, a drug designed to modulate estrogen receptors and PKC-β signaling. CEO Dr. Steven Quay noted that recent data presented at ASCO and AACR conferences reinforce the drug's potential beyond traditional oncology, specifically highlighting its mechanism for addressing rare diseases where current suppression therapies often fall short.
In section Releases
Atossa Therapeutics Reports Q2 Progress Amid Pipeline Expansion
Atossa Therapeutics is pushing its lead candidate, (Z)-endoxifen, into new clinical territory, targeting rare pediatric conditions like Duchenne Muscular Dystrophy and McCune-Albright Syndrome alongside its ongoing breast cancer research, even as the company manages an $8.7 million quarterly operating burn.
Operational results for the period ending June 30, 2026, show a slight tightening of R&D spending, which totaled $4.9 million for the quarter—an 11% dip compared to the same period last year. This reduction was primarily driven by the conclusion of certain preclinical trials. Meanwhile, general and administrative costs rose to $3.8 million, largely due to legal fees associated with settled patent litigation. As Atossa completes enrollment for its Phase 2 EVANGELINE study, the company continues to leverage its Orphan Drug and Rare Pediatric Disease designations from the FDA, positioning (Z)-endoxifen as a potential candidate for future priority review vouchers.
Comments (0)
No comments yet. Be the first!